(E)-5-(2-bromovinyl)-2′-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase-expressing cells

Cancer Gene Therapy

Volumn 8, Issue 5, 2001, Pages 388-396

  Hamel, Wolfgang ^a,b   Zirkel, Dorothea ^c   Mehdorn, H Maximilian ^b   Westphal, Manfred ^c   Israel, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

(E) 5 (2 bromovinyl) 2 deoxyuridine (BVDU); Enzyme prodrug gene therapy; Ganciclovir (GCV); Herpes simplex virus thymidine kinase (HSV tk)

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; GANCICLOVIR; PRODRUG; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GLIOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; CELL DEATH; DRUG RESISTANCE; DRUG SYNERGISM; ENZYME INDUCTION; GANCICLOVIR; HUMANS; MICE; SIMPLEXVIRUS; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0034922609     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700322     Document Type: Article

References (47)

1. In search of a selective antiviral chemotherapy
2. Anticellular effects of 9-(2-hydroxyethoxymethyl)guanine against herpes simplex virus-transformed cells
3. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information
4. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type I thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds
5. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
6. Curability of tumors bearing the herpes thymidine kinase transferred by a retroviral vector
7. Metabolic suicide genes in gene therapy
8. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
9. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
10. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine
11. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues
12. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2
13. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
14. Bystander killing induces apoptosis and is inhibited by forskolin
15. The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice
16. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells
17. On the mechanism of selective inhibition of herpes virus replication by (E)-5-(2-bromovinyl)-2′-deoxyuridine
18. Oral BVDU treatment of varicella and zoster in children with cancer
19. Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella zoster virus infections in severely immunosuppressed patients: A preliminary clinical trial
20. Oral (E)-5-(2-bromovinyl)-2′ deoxyuridine treatment of severe herpes zoster in cancer patients
21. (E)-5-(2-bromovinyl)-2′-deoxyuridine therapy of herpes zoster diseases in patients with malignant primary diseases
22. Thymidylate synthase is the principal target enzyme for the cytostatic action of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene
23. Specific phosphorylation of (E)-5-(2-iodovinyl)-2′-deoxyuridine by herpes simplex virus-infected cells
24. Metabolic fate of (E)-5-(2-bromovinyl)-2′-deoxyuridine in herpes simplex virus- and mock-infected cells
25. Varicella zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer
26. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production
27. Use of retroviral vectors for gene transfer and expression
28. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
29. Strategies for the measurement of the inhibitory effects of thymidine analogs on the activity of thymidylate synthase in intact murine leukemia L1210 cells
30. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy
31. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
32. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
33. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro
34. The search for synergy: A critical review from a response surface perspective
35. Synergism, antagonism, and potentiation in chemotherapy. An overview
36. What is synergy?
37. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity
38. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy
39. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies
40. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo
41. Enzyme prodrug gene therapy: Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer
42. Incorporation of E-5-(2-halovinyl)-2′-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells
43. Anti-recombinogenic and convertible co-mutagenic effects of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted pyrimidine nucleoside analogs in S. cerevisiae MP1
44. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells
45. Potential of varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells
46. Bystander effect of purine nucleoside analogues in HSV-tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues
47. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the varicella zoster or the herpes simplex virus thymidine kinase